

| | | | | |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| Sheet | 1 | 20 | Attorney Docket Number | 03207556 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|------------------------------|------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code* (if known) | | | |
| ICC/ | A1 | 4045564 | 08/30/77 | Berntsson, et al. | |
| | A2 | 4182766 | 01/08/80 | Krasso, et al. | |
| | A3 | 4252790 | 02/24/81 | Higuchi | |
| | A4 | 4255431 | 03/10/81 | Junggren, et al. | |
| | A5 | 4337257 | 06/29/82 | Junggren, et al. | |
| | A6 | 4359465 | 11/16/82 | Ruwart | |
| | A7 | 4414216 | 11/08/83 | Kawakita, et al. | |
| | A8 | 4472409 | 09/18/84 | Senn-Bilfinger | |
| | A9 | 4508905 | 04/02/85 | Junggren, et al. | |
| | A10 | 4544750 | 10/01/85 | Brandstrom, et al. | |
| | A11 | 4738974 | 04/19/88 | Brandstrom, et al. | |
| | A12 | 4786505 | 11/22/88 | Lovgren, et al. | |
| | A13 | 4853230 | 08/01/89 | Lovgren, et al. | |
| | A14 | 4965351 | 10/23/90 | Caruso, et al. | |
| | A15 | 4985548 | 01/15/91 | Caruso, et al. | |
| | A16 | 4990535 | 02/05/91 | Cho et al. | |
| | A17 | 5008278 | 04/16/91 | Brandstrom, et al. | |
| | A18 | 5013743 | 05/07/91 | Iwahi, et al. | |
| | A19 | 5019584 | 05/28/91 | Brandstrom, et al. | |
| | A20 | 5025024 | 06/18/91 | Brandstrom, et al. | |
| | A21 | 5039806 | 08/13/91 | Brandstrom, et al. | |
| | A22 | 5045321 | 09/03/91 | Makino, et al. | |
| | A23 | 5075323 | 12/24/91 | Fain, et al. | |
| | A24 | 5093132 | 03/03/92 | Makino, et al. | |
| | A25 | 5093342 | 03/03/92 | Tomoi, et al. | |
| | A26 | 5106862 | 04/21/92 | Briving, et al. | |
| | A27 | 5124158 | 06/23/92 | Ruwart, et al. | |
| | A28 | 5215974 | 06/01/93 | Alminger, et al. | |
| | A29 | 5294439 | 03/15/94 | Yamaska | |
| | A30 | 5339700 | 08/23/94 | Wright, et al. | |
| | A31 | 5374730 | 12/20/94 | Slemon, et al. | |
| | A32 | 5385739 | 01/31/95 | Debregeas, et al. | |
| | A33 | 5386032 | 01/31/95 | Brandstrom | |
| | A34 | 5391752 | 02/21/95 | Hoernner, et al. | |
| ICC/ | A35 | 5395323 | 03/07/95 | Berglund | |
| 1334284.1 | | /Celia Chang/ | | Date Considered | 6/14/07 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 808. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1430, Alexandria, VA 22313-1430.
If you need assistance in completing this form, call 1-800-PTO-6199 (1-800-768-6199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

| | | | | |
|-------|---|----|------------------------|-------------------|
| Sheet | 2 | 20 | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No.† | Document Number | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|-----------------------|-----------|------------------------------|------------------------------|--|---|
| | | Number-Kind Code* (if known) | | | |
| /CC/ | A36 | 5399700 | 03/21/95 | Min, et al. | |
| | A37 | 5417980 | 05/23/95 | Goldman, et al. | |
| | A38 | 5430042 | 07/04/95 | Lindberg, et al. | |
| | A39 | 5447923 | 09/05/95 | Castrenich, et al. | |
| | A40 | 5470983 | 11/28/95 | Slemon, et al. | |
| | A41 | 5504082 | 04/02/96 | Kawakita, et al. | |
| | A42 | 5589491 | 12/31/96 | Nakanishi, et al. | |
| | A43 | 5599794 | 02/04/97 | Eek, et al. | |
| | A44 | 5629305 | 05/13/97 | Eek, et al. | |
| | A45 | 5633244 | 05/27/97 | Eek, et al. | |
| | A46 | 5639478 | 06/17/97 | Makino, et al. | |
| | A47 | 5690960 | 11/25/97 | Bengtsson, et al. | |
| | A48 | 5693818 | 12/02/97 | Von Unge | |
| | A49 | 5714504 | 02/03/98 | Lindberg, et al. | |
| | A50 | 5714505 | 02/03/98 | Hasselkus | |
| | A51 | 5731002 | 03/24/98 | Olovson, et al. | |
| | A52 | 5753265 | 05/19/98 | Bergstrand, et al. | |
| | A53 | 5762962 | 06/09/98 | Georgiades et al. | |
| | A54 | 5766622 | 06/16/98 | Nelson | |
| | A55 | 5776765 | 07/07/98 | Graham, et al. | |
| | A56 | 5798120 | 08/25/98 | Tomohisa, et al. | |
| | A57 | 5814338 | 09/29/98 | Veronesi | |
| | A58 | 5817338 | 10/06/98 | Bergstrand, et al. | |
| | A59 | 5840737 | 11/24/98 | Phillips | |
| | A60 | 5876759 | 03/02/99 | Gowan | |
| | A61 | 5877192 | 03/02/99 | Lindberg, et al. | |
| | A62 | 5879708 | 03/09/99 | Makino, et al. | |
| | A63 | 5883102 | 03/16/99 | Hamley, et al. | |
| | A64 | 5885594 | 03/23/99 | Nilsen, et al. | |
| | A65 | 5900424 | 05/04/99 | Kallstrom, et al. | |
| | A66 | 5929244 | 07/27/99 | Von Unge | |
| | A67 | 5939091 | 08/17/99 | Eoga, et al. | |
| | A68 | 5948789 | 09/07/99 | Larsson, et al. | |
| | A69 | 5955107 | 09/21/99 | Augello, et al. | |
| /CC/ | A70 | 5958955 | 09/28/99 | Gustavsson, et al. | |

13342B4.1

/Celia Chang/

Date
Considered 06/14/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-785-9199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/722,184 |
| Filing Date | November 25, 2003 |
| First Named Inventor | Phillips |
| Art Unit | 1625 |
| Examiner Name | Celia C. Chang |
| Attorney Docket Number | 03207556 |

Sheet 3 of 20

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. 1 | Document Number | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|------------|------------------------------|------------------------------|--|---|
| | | Number-Kind Code* (if known) | | | |
| /CCI/ | A71 | 5962022 | 10/05/99 | Bolt, et al. | |
| | A72 | 5965162 | 10/12/99 | Fuisz, et al. | |
| | A73 | 5972389 | 10/26/99 | Shell, et al. | |
| | A74 | 5979515 | 11/09/99 | Olsson | |
| | A75 | 6013281 | 01/11/00 | Lundberg, et al. | |
| | A76 | 6017560 | 01/25/00 | Makino, et al. | |
| | A77 | 6090827 | 07/18/00 | Erickson, et al. | |
| | A78 | 6123962 | 09/26/00 | Makino, et al. | |
| | A79 | 6124464 | 09/26/00 | Hogberg, et al. | |
| | A80 | 6132770 | 10/17/00 | Lundberg | |
| | A81 | 6132771 | 10/17/00 | Depui, et al. | |
| | A82 | 6136344 | 10/24/00 | Depui, et al. | |
| | A83 | 6143771 | 11/07/00 | Lindberg, et al. | |
| | A84 | 6147103 | 11/14/00 | Anousis, et al. | |
| | A85 | 6150380 | 11/21/00 | Lovqvist, et al. | |
| | A86 | 6162816 | 12/19/00 | Bohlin, et al. | |
| | A87 | 6166213 | 12/26/00 | Anousis, et al. | |
| | A88 | 6183776 | 02/06/01 | Depui, et al. | |
| | A89 | 6248363 | 06/19/01 | Patel et al. | |
| | A90 | 6274173 | 08/14/01 | Sachs, et al. | |
| | A91 | 6284271 | 09/04/01 | Lundberg, et al. | |
| | A92 | 2002/0192299 | 12/19/02 | Taneja et al. | |
| | A93 | 6569453 | 04/27/03 | Linder et al. | |
| | A94 | 5703097 | 12/30/97 | Kim et al. | |
| | A95 | 6280773 | 08/29/01 | Cho et al. | |
| | A96 | 2005/0370370 | 02/17/06 | Warren | |
| /CCI/ | A97 | 6749867 | 06/15/04 | Robinson | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. 1 | Foreign Patent Document | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | † |
|--------------------|------------|---|------------------------------|--|---|---|
| | | Country Code* Number* Kind Code* (if known) | | | | |
| /CCI/ | B1 | CA 1234118 | 03/15/88 | | | |
| | B2 | CA2378018 | 01/18/01 | | | |
| | B3 | CA2432184 | 07/11/02 | | | |
| /CCI/ | B4 | DK 19752843 | 07/01/99 | (missing) | | |

1334284.1

/Celia Chang/

Date
Considered

06/14/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22314-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-755-9199) and select option 2.

| | | | | |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| Sheet | 4 | 20 | Attorney Docket Number | 03207556 |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|------------|---|------------------------------|--|--|----|
| Examiner Initials* | Cite No. * | Foreign Patent Document | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | †* |
| | | Country Code* Number* Kind Code* (If known) | | | | |
| /CC/ | B5 | GB 2189698 | 11/04/87 | | | |
| | B6 | EP 0005129 | 10/31/79 | | | |
| | B7 | EP 0244380 | 11/04/87 | | | |
| | B8 | EP 0247983 | 12/02/87 | | | |
| | B9 | EP 0308515 | 03/29/89 | | | |
| | B10 | EP 0315964 | 05/17/89 | | | |
| | B11 | EP 0394471 | 10/31/90 | | | |
| | B12 | EP 0414847 | 03/06/91 | | | |
| | B13 | EP 0436620 | 07/17/91 | | | |
| | B14 | EP 0452697 | 10/23/91 | | | |
| | B15 | EP 0465254 | 01/08/92 | | | |
| | B16 | EP 0480691 | 04/15/92 | | | |
| | B17 | EP 0237200 | 07/01/92 | | | |
| | B18 | EP 0496437 | 07/29/92 | | | |
| | B19 | EP 0502556 | 09/09/92 | | | |
| | B20 | EP 0338861 | 01/20/93 | | | |
| | B21 | EP 0248634 | 07/21/93 | | | |
| | B22 | EP 0565210 | 10/13/93 | | | |
| | B23 | EP 0567201 | 10/27/93 | | | |
| | B24 | EP 0567643 | 11/03/93 | | | |
| | B25 | EP 0587659 | 03/23/94 | | | |
| | B26 | EP 0636364 | 02/01/95 | | | |
| | B27 | EP 0652751 | 05/17/95 | | | |
| | B28 | EP 0654471 | 05/24/95 | | | |
| | B29 | EP 0696921 | 02/21/96 | | | |
| | B30 | EP 1004305 | 05/21/00 | | | |
| | B31 | ES 2024993 | 12/31/90 | | | |
| | B32 | JP 48 103567 | 12/25/73 | | | |
| | B33 | JP 49 005967 | 01/19/74 | | | |
| | B34 | JP 49 013172 | 02/05/74 | | | |
| | B35 | JP 49 020173 | 02/22/74 | | | |
| | B36 | JP 49 020174 | 02/22/74 | | | |
| | B37 | JP 49 041198 | 07/11/74 | | | |
| | B38 | JP 49 093537 | 09/05/74 | | | |
| /CC/ | B39 | JP 49 095997 | 09/11/74 | | | |
| 1334284.1 | | /Celia Chang/ | | Date Considered | 06/14/07 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |
| Sheet | 5 | 20 | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|------------|--|------------------------------|--|---|----|
| Examiner Initials* | Cite No. * | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Lines, Where Relevant Passages or Relevant Figures Appear | †* |
| /CC/ | B40 | JP 50 052065 | 05/09/75 | | | |
| | B41 | JP 50 112373 | 09/03/75 | | | |
| | B42 | JP 50 142565 | 11/17/75 | | | |
| | B43 | JP 51 016669 | 02/10/76 | | | |
| | B44 | JP 51 131875 | 11/16/76 | | | |
| | B45 | JP 52 005769 | 01/17/77 | | | |
| | B46 | JP 52 014776 | 02/03/77 | | | |
| | B47 | JP 52 097978 | 08/17/77 | | | |
| | B48 | JP 52 102416 | 08/27/77 | | | |
| | B49 | JP 53 059675 | 05/29/78 | | | |
| | B50 | JP 55 019211 | 05/24/80 | | | |
| | B51 | JP 56 061311 | 05/26/81 | | | |
| | B52 | JP 61 221117 | 10/01/86 | | | |
| | B53 | JP 62 145083 | 06/29/87 | | | |
| | B54 | JP 62 258316 | 11/10/87 | | | |
| | B55 | JP 62 258320 | 11/10/87 | | | |
| | B56 | JP 62 277322 | 12/02/87 | | | |
| | B57 | JP 62 283964 | 12/09/87 | | | |
| | B58 | JP 02 022225 | 01/25/90 | | | |
| | B59 | JP 03 163018 | 11/20/90 | | | |
| | B60 | JP 03 034967 | 02/14/91 | | | |
| | B61 | JP 03 048680 | 03/01/91 | | | |
| | B62 | JP 03 052887 | 03/07/91 | | | |
| | B63 | JP 05 117268 | 05/14/93 | | | |
| | B64 | JP 05 194225 | 08/03/93 | | | |
| | B65 | JP 05 255088 | 10/05/93 | | | |
| | B66 | JP 05 294831 | 11/09/93 | | | |
| | B67 | JP 06 092853 | 04/05/94 | | | |
| | B68 | JP 06 100449 | 04/12/94 | | | |
| | B69 | JP 07 033659 | 02/03/95 | | | |
| | B70 | JP 09 087110 | 03/31/97 | | | |
| | B71 | JP 10 017470 | 01/20/98 | | | |
| | B72 | JP 10 017471 | 01/20/98 | | | |
| | B73 | JP 2000212180 | 08/02/00 | | | |
| /CC/ | B74 | JP 2000355540 | 12/26/00 | | | |
| 1334284.1 | | /Celia Chang/ | | Date Considered | 06/14/07 | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |
| Sheet | 6 | 20 | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|------------|--|------------------------------|--|---|---|
| Examiner Initials* | Cite No. * | Foreign Patent Document Country Code ¹ -Number ² -Kind Code ³ (if known) | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Lines, Where Relevant Passages or Relevant Figures Appear | † |
| /CC/ | B75 | KR 9603605 | 03/20/96 | | | |
| | B76 | KR 9611238 | 08/21/96 | | | |
| | B77 | KR 9611390 | 08/22/96 | | | |
| | B78 | RO 88351 | 04/30/86 | | | |
| | B79 | WO 9204898 | 04/02/92 | | | |
| | B80 | WO 9208716 | 05/29/92 | | | |
| | B81 | WO 9305770 | 04/01/93 | | | |
| | B82 | WO 9400112 | 01/06/94 | | | |
| | B83 | WO 9402140 | 02/03/94 | | | |
| | B84 | WO 9402141 | 02/03/94 | | | |
| | B85 | WO 9501783 | 01/19/95 | | | |
| | B86 | WO 9507913 | 03/23/95 | | | |
| | B87 | WO 9515962 | 06/15/95 | | | |
| | B88 | WO 9523594 | 09/08/95 | | | |
| | B89 | WO 9532957 | 12/07/95 | | | |
| | B90 | WO 9532959 | 12/07/95 | | | |
| | B91 | WO 9601612 | 01/25/96 | | | |
| | B92 | WO 9601622 | 01/25/96 | | | |
| | B93 | WO 9601623 | 01/25/96 | | | |
| | B94 | WO 9601624 | 01/25/96 | | | |
| | B95 | WO 9601625 | 01/25/96 | | | |
| | B96 | WO 9602236 | 02/01/96 | | | |
| | B97 | WO 9616959 | 06/06/96 | | | |
| | B98 | WO 9624338 | 08/15/96 | | | |
| | B99 | WO 9624375 | 08/15/96 | | | |
| | B100 | WO 9638175 | 12/05/96 | | | |
| | B101 | WO 9702020 | 01/23/97 | | | |
| | B102 | WO 9702021 | 01/23/97 | | | |
| | B103 | WO 9709964 | 03/20/97 | | | |
| | B104 | WO 9725030 | 07/17/97 | | | |
| | B105 | WO 9725064 | 07/17/97 | | | |
| | B106 | WO 9725065 | 07/17/97 | | | |
| | B107 | WO 9725066 | 07/17/97 | | | |
| /CC/ | B108 | WO 9741114 | 11/06/97 | | | |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | |
|--|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |
| Sheet | 7 | 20 | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|------------|---|------------------------------|--|---|---|
| Examiner Initials* | Cite No. * | Foreign Patent Document | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Lines, Where Relevant Passages or Relevant Figures Appear | † |
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| /CC/ | B109 | WO 9748380 | 12/24/97 | | | |
| | B110 | WO 9800114 | 01/08/98 | | | |
| | B111 | WO 9802368 | 01/22/98 | | | |
| | B112 | WO 9816228 | 04/23/98 | | | |
| | B113 | WO 9828294 | 07/02/98 | | | |
| | B114 | WO 9840054 | 09/17/98 | | | |
| | B115 | WO 9850019 | 11/12/98 | | | |
| | B116 | WO 9853803 | 12/03/98 | | | |
| | B117 | WO 9854171 | 12/03/98 | | | |
| | B118 | WO 9900380 | 01/07/99 | | | |
| | B119 | WO 9908500 | 02/25/99 | | | |
| | B120 | WO 9925323 | 05/27/99 | | | |
| | B121 | WO 9925711 | 05/27/99 | | | |
| | B122 | WO 9927917 | 06/10/99 | | | |
| | B123 | WO 9929299 | 06/17/99 | | | |
| | B124 | WO 9929320 | 06/17/99 | | | |
| | B125 | WO 9932091 | 07/01/99 | | | |
| | B126 | WO 9932093 | 07/01/99 | | | |
| | B127 | WO 9945004 | 09/10/99 | | | |
| | B128 | WO 9953918 | 10/28/99 | | | |
| | B129 | WO 9955705 | 11/04/99 | | | |
| | B130 | WO 9955706 | 11/04/99 | | | |
| | B131 | WO 0009092 | 02/24/00 | | | |
| | B132 | WO 0010999 | 03/02/00 | | | |
| | B133 | WO 0015195 | 03/23/00 | | | |
| | B134 | WO 0026185 | 05/11/00 | | | |
| | B135 | WO 0027366 | 05/18/00 | | | |
| | B136 | WO 0028975 | 05/25/00 | | | |
| | B137 | WO 0030612 | 06/02/00 | | | |
| | B138 | WO 0035448 | 06/22/00 | | | |
| | B139 | WO 0044744 | 08/03/00 | | | |
| | B140 | WO 0045817 | 08/10/00 | | | |
| | B141 | WO 0050038 | 08/31/00 | | | |
| | /CC/ | B142 | WO 0069438 | 11/23/00 | | |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-788-9199) and select option 2.

| | | | | |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |
| Sheet | 8 | 20 | | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|------------|--|------------------------------|--|---|----|
| Examiner Initials* | Cite No. * | Foreign Patent Document Country Code* Number* Kind Code* (if known) | Publication Date MM-DD-YY | Name of Patentee or Applicant of Cited Document | Pages, Lines, Where Relevant Passages or Relevant Figures Appear | 1* |
| /CC/ | B143 | WO 0078293 | 12/28/00 | | | |
| | B144 | WO 0103707 | 01/18/01 | | | |
| | B145 | WO 0124780 | 04/12/01 | | | |
| | B146 | WO 0134573 | 05/17/01 | | | |
| /CC/ | B147 | WO 03017980 | 03/06/03 | | | |

| NON PATENT LITERATURE | | |
|-----------------------|------------|---|
| Examiner Initials* | Cite No. * | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C1 | Antacid Bottle Instruction |
| | C2 | AL-ASSI, et al., "Treatment of Helicobacter Pylori Infection With Omeprazole-Amoxicillin Combination Therapy Versus Ranitidine/Sodium Bicarbonate-Amoxicillin", <u>The American Journal of Gastroenterology</u> , Vol. 90, No. 9, pp. 1411-14 (September 1995). |
| | C3 | ANDERSSON, et al., "Pharmacokinetic Studies With Esomeprazole, the (S)-Isomer of Omeprazole", <u>Clinical Pharmacokinetics</u> , Vol. 40, No. 6, pp. 411-426 (2001). |
| | C4 | ANDERSSON, T., "Pharmacokinetics, Metabolism and Interactions of Acid Pump Inhibitors: Focus on Omeprazole, Lansoprazole and Pantoprazole", <u>Clin. Pharmacokinet.</u> , Vol. 31, No. 1, pp. 9-28 (July 1996). |
| | C5 | ANDERSSON, T., et al., "Pharmacokinetics and Bioavailability of Omeprazole After Single and Repeated Oral Administration in Healthy Subjects", <u>Br. J. Clin. Pharmac.</u> , Vol. 29, pp. 557-563 (1990). |
| | C6 | ANDERSSON, T., et al., "Pharmacokinetics of [¹⁴ C]Omeprazole in Patients with Liver Cirrhosis", <u>Clin Pharmacokinet.</u> , Vol. 24, No. 1, pp. 71-78 (1993). |
| | C7 | ANDERSSON, T., et al., "Pharmacokinetics of Various Single Intravenous and Oral Doses of Omeprazole", <u>European Journal of Clinical Pharmacology</u> , Vol. 39, pp. 195-197 (1990). |
| | C8 | ARVIDSSON, et al., "Peak Distortion in the Column Liquid Chromatographic Determination of Omeprazole Dissolved in Borax Buffer", <u>Journal of Chromatography</u> , Vol. 586, Part 2, pp. 271-276 (1991). |
| | C9 | BALABAN, D., et al., "Nasogastric Omeprazole: Effects on Gastric pH in Critically Ill Patients", <u>The American Journal of Gastroenterology</u> , Vol. 92, No. 1, pp. 79-83 (1997). |
| | C10 | BALLARD, E., et al., "Bioequivalence Between Lansoprazole Sachet for Suspension and Intact Capsule," <u>Gastroenterology</u> , Vol. 120 (No. %, Suppl. 1), pg. A-245 (2001). |
| /CC/ | C11 | BALLESTEROS, et al., "Bolus or Intravenous Infusion of Rantidine: Effects on Gastric pH and Acid Secretion. A Comparison of Relative Efficacy and Cost", <u>Annals of Internal Medicine</u> , Vol. 112, No. 5, pp. 334 - 339 (1990). |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 606. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 10 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | |
|---|---|----|--------------------------|-------------------|
| Substitute for form 1448/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |
| Sheet | 9 | 20 | | |

| NON PATENT LITERATURE | | |
|--|----------|---|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issu number(s), publisher, city and/or country where published. |
| ICC/ | C12 | BARIE & HARIRI, "Therapeutic Use of Omeprazole For Refractory Stress-Induced Gastric Mucosal Hemorrhage", <u>Critical Care Medicine</u> , Vol. 20, No. 6, pp. 899-901 (1992). |
| | C13 | BEEKMAN, S. M., "Preparation and Properties of New Gastric Antacids I", <u>J. Pharm Assoc.</u> , Vol. 49, pp. 191-200, (1960). |
| | C14 | Bennett & Dickson, eds., "Gastrointestinal Drugs", <u>The American Medical Association Drug Evaluation</u> , Vol. 2, The American Medical Association, Chicago, Vol 1:8. |
| | C15 | BLUM, A., "Therapeutic Approach to Ulcer Healing," <u>The American Journal of Medicine</u> , Volume 79 (Suppl. 2C), pp.8-14 (August 30,1985) |
| | C16 | BONE, "Let's Agree on Terminology: Definition of Sepsis", <u>Critical Care Medicine</u> , Vol. 19, No. 7, pp. 973-976 (July 1991). |
| | C17 | BORELLA, et al., Abstract for "Gastric Antisecretory and Anitular/Cytoprotective Effects of 2-cyano-3(ethylthio-3methylthio)-2-Propenoic Acid Methyl Ester", Wyeth-Ayerst Res., Inc. (1989) |
| | C18 | BORRERO, et al., "Antacids vs. Sucralfate in Preventing Acute Gastrointestinal Tract Bleeding in Abdominal Aortic Surgery. A Randomized Trial in 50 Patients", <u>Arch. Surg.</u> , Vol. 121, pp. 810-12 (July 1986). |
| | C19 | BRUNTON, "Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers", <u>The Pharmacologic Basis of Therapeutics</u> , p. 897-913 (1990). |
| | C20 | CANTU & KOREK, "Central Nervous System Reactions to Histamine-2 Receptor Blockers", <u>Annals of Internal Medicine</u> , Vol. 114, No. 12, pp. 1027-34 (1991). |
| | C21 | CAOS, A., et al., "Rabeprazole for the Prevention of Pathologic and Symptomatic Relapse of Erosive or Ulcerative Gastroesophageal Reflux Disease", <u>The American Journal of Gastroenterology</u> , Vol. 95, No. 11, pp. 3081-3088 (2000). |
| | C22 | CARROLL, M., et al., "Nasogastric Administration of Omeprazole for Control of Gastric pH" 10 th World Congresses of Gastroenterology, Abstracts (October 2-7, 1994). |
| | C23 | CEDERBERG, C., et al., "Omeprazole: Pharmacokinetics and Metabolism in Man", <u>Scand. J. Gastroenterol.</u> , Vol. 24, Suppl. 166, pp. 33-40 (1989). |
| | C24 | CEDERBERG, et al., "Effect of Once Daily Intravenous and Oral Omeprazole on 24-Hour Intragastric Acidity in Healthy Subjects", <u>Scand. J. Gastroenterol.</u> , Vol. 28, No. 2, pp. 179-184 (February 1993). |
| | C25 | CHING, et al., "Antacids - Indications and Limitations", <u>Drugs</u> , Vol. 47, No. 2, pp. 305-317 (February 1994). |
| | C26 | CIOFFI, et al., "Comparison of Acid Neutralizing and Non-acid Neutralizing Stress Ulcer Prophylaxis in Thermally Injured Patients", <u>The Journal of Trauma</u> , Vol. 36, pp. 541-47 (1994). |
| ICC/ | C27 | COOK, et al., "Nosocomial Pneumonia and the Role of Gastric pH: A Meta Analysis", <u>Chest</u> , Vol. 100, No. 1, pp. 7-13 (July 1991). |
| 1334284.1 /Celia Chang/ Date Considered 06/14/07 | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kind's Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 15 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | |
|--|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |
| Sheet | 10 | 20 | | |

| NON PATENT LITERATURE | | |
|-----------------------|-----------------------|--|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C28 | COOK, et al., "Risk Factors For Gastrointestinal Bleeding in Critically Ill Patients. Canadian Critical Care Trial Groups", <u>The New England Journal of Medicine</u> , Vol. 330, No. 6, pp. 377-81 (February 10, 1994). |
| | C29 | COOK, et al., "Stress Ulcer Prophylaxis in the Critically Ill: A Meta Analysis", <u>The American Journal of Medicine</u> , Vol. 91, pp. 519-527 (November 1991). |
| | C30 | CRILL, et al., "Upper Gastrointestinal Tract Bleeding in Critically Ill Pediatric Patients", <u>Pharmacotherapy</u> , Vol. 19, No. 2, pp. 162-180 (February 1999). |
| | C31 | CZAJA, et al., "Acute Gastroduodenal Disease After Thermal Injury: An Endoscopic Evaluation of Incidence and Natural History", <u>The New England Journal of Medicine</u> , Vol. 291, pp. 925-929 (October 31, 1974). |
| | C32 | DEAKIN, et al., "Therapeutic Progress - Review XXXIII: Are We Making Progress In The Drug Treatment of Oesophageal Disease?", <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 13, No. 6, pp. 365-374 (December 1988). |
| | C33 | DI IORIO, et al., "Aluminum and Phosphorus Urinary Excretion After Modifying Gastric Acid Secretion In Normal Subjects", <u>Trace Elements and Electrolytes</u> , Vol. 13, No. 1, pp. 47-49 (1996). |
| | C34 | DIGIACINTO, et al., "Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes", <u>Annals of Pharmacotherapy</u> , Vol. 34, No. 5, pp. 600-605 (May 2000). |
| | C35 | DOAN, et al., "Comparative Pharmacokinetics and Pharmacodynamics of Lansoprazole Oral Capsules and Suspension in Healthy Subjects", <u>American Journal of Health-System Pharmacists</u> , Vol. 58, No. 16, pp. 1512-19 (August 15, 2001). |
| | C36 | DOBKIN, et al., "Does pH Paper Accurately Reflect Gastric pH?", <u>Critical Care Medicine</u> , Vol. 18, pp. 985-88 (September 1990). |
| | C37 | DRIKS, et al., "Nosocomial Pneumonia in Intubated Patients Given Sucralfate As Compared With Antacids or Histamine Type 2 Blockers. The Role of Gastric Colonization", <u>New England Journal Medicine</u> , Vol. 317, pp. 1376-82 (1987). |
| | C38 | EISENBERG, et al., "Prospective Trial Comparing a Combination pH Probe-Nasogastric Tube With Aspirated Gastric pH in Intensive Care Unit Patients", <u>Critical Care Medicine</u> , Vol. 18, No. 10, 1092-95 (1990). |
| | C39 | EPKE, A., et al., "Effect of Various Salts on the Stability of Lansoprazole, Omeprazole, and Pantoprazole as Determined by High-Performance Liquid Chromatography", <u>Drug Development and Industrial Pharmacy</u> , Vol. 25, No. 9, pp. 1057-1065 (1999). |
| /CC/ | C40 | FABIAN, et al., "Pneumonia and Stress Ulceration in Severely Injured Patients. A Prospective Evaluation of the Effects of Stress Ulcer Prophylaxis", <u>Arch. Surg.</u> , Vol. 128, p. 185-91 (1993). |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-0199 (1-800-765-0199) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)**Complete if Known**

| | | | | |
|-------|----|----|------------------------|-------------------|
| Sheet | 11 | 20 | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| | | | Attorney Docket Number | 03207556 |

NON PATENT LITERATURE

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|--------------------|-----------------------|--|
| ICC/ | C41 | FELLENUS, et al., "Substituted Benzimidazoles Inhibit Gastric Acid Secretions by Blocking H ⁺ /K ⁺ - ATPase", <u>Nature</u> , Vol. 290, Part 5802, pp. 159-61 (1981). |
| | C42 | FERRON et al., "Oral Bioavailability of Pantoprazole Suspended in Sodium Bicarbonate Solution", <u>Am J Health-Syst Pharm</u> , Vol. 60, pp. 1324-1328 (July 1, 2003) |
| | C43 | FIDDIAN-GREEN, et al., Predictive Value of Intramural pH and Other Risk Factors For Massive Bleeding From Stress Ulceration", <u>Gastroenterology</u> , Vol. 85, No. 3, pp. 613-20 (1983). |
| | C44 | FITTON, A., et al., "Pantoprazole, A Review of its Pharmacological Properties and Therapeutic Use in Acid-Related Disorders", <u>Drugs</u> , Vol. 51, No. 3, pp. 460-482 (March 1996). |
| | C45 | FRYKLUND, et al., "Function and Structure of Parietal Cells After H ⁺ /K ⁺ -ATPase Blockade, <u>American Journal of Physiology</u> , Vol. 254, pp. G399-407 (1988). |
| | C46 | FUCHS, C., "Antacids, Their Function, Formulation and Evaluation", <u>Drug and Cosmetic Industry</u> , Vol. 64, pp. 692-773, (1949). |
| | C47 | GAFTER, et al., "Thrombocytopenia Associated with Hypersensitivity to Rantidine: Possible Cross-Reactivity With Cimetidine", <u>American Journal of Gastroenterology</u> , Vol. 84, No. 5, pp. 560-62 (1989). |
| | C48 | GARNER, et al., "CDC Definitions for Nosocomial Infections", <u>American Journal Infection Control</u> , Vol. 16, No. 7, pp. 128-40 (1988). |
| | C49 | GARNETT, "Efficacy, Safety, and Cost Issues in Managing Patients With Gastroesophageal Reflux Disease", <u>Am. J. Hosp. Pharm.</u> , Vol. 50, No. 4 (Suppl. 1), pp. S11-18 (April 1993). |
| | C50 | GRAY, et al., "Influence of Insulin Antibodies on Pharmacokinetics and Bioavailability of Recombinant Human and Highly Purified Beef Insulins in Insulin Dependent Diabetics", <u>British Medical Journal</u> , Vol. 290, pp. 1687-91 (June 8, 1985). |
| | C51 | HARDY, et al., "Inhibition of Gastric Secretion by Omeprazole and Efficiency of Calcium Carbonate on the Control of Hyperphosphatemia in Patients on Chronic Hemodialysis", <u>Artificial Organs</u> , Vol. 22, No. 7, pp. 569-573 (July 1998). |
| | C52 | HATLEBAKK, J., et al., "Lansoprazole Capsules and Amoxicillin Oral Suspension in the Treatment of Peptic Ulcer Disease", <u>Scand. J. Gastroenterol.</u> , Vol. 30, No. 11, pp. 1053-57 (1995). |
| | C53 | HEATH, et al., "Intragastric pH Measurement Using a Novel Disposable Sensor", <u>Intensive Care Medicine</u> , Vol. 14, No. 3, pp. 232-35 (1988). |
| | C54 | HIXSON, et al., "Current Trends in the Pharmacotherapy for Gastroesophageal Reflux Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 717-723 (April 1992). |
| ICC/ | C55 | HIXSON, et al., "Current Trends in the Pharmacotherapy for Peptic Ulcer Disease", <u>Arch. Intern. Med.</u> , Vol. 152, No. 4, pp. 726-732 (April 1992). |

1334284.1

/Celia Chang/

Date Considered 06/14/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22319-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | |
|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/722,184 |
| | | Filing Date | November 25, 2003 |
| | | First Named Inventor | Phillips |
| | | Art Unit | 1625 |
| | | Examiner Name | Celia C. Chang |
| | | Attorney Docket Number | 03207556 |
| Sheet | 12 | 20 | |

| NON PATENT LITERATURE | | |
|-----------------------|---------------|--|
| Examiner Initials* | Cite No. 1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C56 | HOLBERT, J., et al., "A Study of Antacid Buffers: I. The Time Factor in Neutralization of Gastric Acidity", <u>Journal of The American Pharmaceutical Association (Scientific Edition)</u> , Vol. 36, pp. 149-151 (1947). |
| | C57 | HOLT, S., et al., "Omeprazole, Overview and Opinion", <u>Digestive Diseases and Sciences</u> , Vol. 36, No. 4, pp. 385-393 (April 1991). |
| | C58 | HORN, J., "The Proton-Pump Inhibitors: Similarities and Differences", <u>Clinical Therapeutics</u> , Vol. 22, No. 3, pp. 266-280 (2000). |
| | C59 | HOWDEN, et al., "Oral Pharmacokinetics of Omeprazole", <u>European Journal of Clinical Pharmacology</u> , Vol. 26, pp. 641-643 (1984). |
| | C60 | HUMPHRIES, et al., "Review Article: Drug Interactions With Agents Used to Treat Acid-Related Diseases", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 13, Suppl. 3, pp. 18-26 (August 1999). |
| | C61 | JUNGNICKEL, P., "Pantoprazole: A New Proton Pump Inhibitor", <u>Clinical Therapeutics</u> , Vol. 22, No. 11, pp. 1268-1293 (2000). |
| | C62 | KAROL, M. et al., "Pharmacokinetics of Lansoprazole in Hemodialysis Patients", <u>J Clin Pharmacol</u> , Vol. 35, pp. 815-820 (August 1995). |
| | C63 | KIHIRA, K., et al., "Endoscopic Topical Therapy for the Treatment of Helicobacter Pylori Infection", <u>Journal of Gastroenterology</u> , Vol. 31, Suppl 9, pp. 66-68 (November 1996). |
| | C64 | KIILRICH, et al., "Effect of Intravenous Infusion of Omeprazole and Rantidine on Twenty-Four-Hour Intragastric pH", <u>Digestion</u> , Vol. 56, pp. 25-30 (1995). |
| | C65 | KORPONAY-SZABO, I., et al., "High Acid Buffering Capacity of Protein Hydrolysate Infant Formulas", <u>Journal of Pediatric Gastroenterology and Nutrition</u> , Vol. 31, Supplement 2, Abstract 956 (August 5-9, 2000). |
| | C66 | KROMER, "Similarities and Differences in the Properties of Substituted Benzimidazoles: A Comparison Between Pantoprazole and Related Compounds", <u>Digestion</u> , Vol. 56, No. 6, pp. 443-454 (1995). |
| | C67 | KROMER, et al., "Differences in pH-Dependent Activation Rate of Substituted Benzimidazoles and Biological in vitro Correlates", <u>Pharmacology</u> , Vol. 56, pp. 57-70, (1998) |
| | C68 | LAGGNER, et al., "Prevention of Upper Gastrointestinal Bleeding in Long Term Ventilated Patients", <u>American Journal of Medicine</u> , Vol. 86, Suppl. 6A, pp. 81-84 (June 9, 1989). |
| | C69 | LANDAHL, S., et al., "Pharmacokinetic Study of Omeprazole in Elderly Healthy Volunteers", <u>Clin. Pharmacokinetics</u> , Vol. 23, No. 6, pp. 469-476 (1992). |
| /CC/ | C70 | LARSON, C., et al., "Bioavailability and Efficacy of Omeprazole Given Orally and By Nasogastric Tube", <u>Digestive Diseases and Sciences</u> , Vol. 41, No. 3, pp. 475-479 (March 1996). |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *End of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-726-9199) and select option 2.

| | | | | |
|--|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| Sheet | 13 | 20 | Attorney Docket Number | 03207556 |

| NON PATENT LITERATURE | | |
|-----------------------|-----------|--|
| Examiner Initials* | Cite No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C71 | LARSON, et al., "Gastric Response to Severe Head Injury", <u>American Journal of Surgery</u> , Vol. 147, pp. 97-105 (January 1984). |
| | C72 | LARSSON, et al., "Gastric Acid Antisecretory Effect of Two Different Dosage Forms of Omeprazole During Prolonged Oral Treatment in the Gastric Fistula Dog", Vol. 23, No. 8, pp. 1013-1019 (1988). |
| | C73 | LASKY, M., et al., "A Prospective Study of Omeprazole Suspension to Prevent Clinically Significant Gastrointestinal Bleeding From Stress Ulcers in Mechanically Ventilated Trauma Patients", <u>The Journal of Trauma: Injury Infection, and Critical Care</u> , Vol. 44, No. 3, pp. 527-533 (March 1998). |
| | C74 | LIN, M., et al., "Evaluation of Buffering Capacity and Acid Neutralizing pH Time Profile of Antacids", <u>J Formos Med Assoc</u> , Vol. 97, No. 10, pp. 704-710 (1998). |
| | C75 | LIND, et al., "Inhibition of Basal and Betazole - and Sham-Feeding-Induced Acid Secretion by Omeprazole in Man", <u>Scand. J. Gastroenterol</u> , Vol. 21, No. 8, pp. 1004-1010 (1986). |
| | C76 | LOCKHART, S. et al., "A Lansoprazole Suspension Formulation As An Alternative to Capsules for Oral Administration", <u>World Congresses of Gastroenterology</u> , Abstract Exh A2074 (September 6-11, 1998). |
| | C77 | LONDONG, et al., "Dose-Response Study of Omeprazole on Meal-Stimulated Gastric-Acid Secretion and Gastrin Release", <u>Gastroenterology</u> , Vol. 85, No. 6, pp. 1373-1378 (1983). |
| | C78 | MACONI, et al., "Prolonging Proton Pump Inhibitor-Based Anti-Helicobacter Pylori Treatment From One to Two Weeks in Duodenal Ulcer: Is It Worthwhile?", <u>Digest Liver Disease</u> , Vol. 32, pp. 275-280 (May 2000). |
| | C79 | MARRONE & SILEN, "Pathogenesis, Diagnosis and Treatment of Acute Gastric Mucosa Lesions", <u>Clinics Gastroenterology</u> , Vol. 13, No. 2, pp. 635-60 (May 1984). |
| | C80 | MARTIN, A., et al., <u>Physical Pharmacy - Physical Chemicals Principles in the Pharmaceutical Sciences</u> , Fourth Edition, (1993) |
| | C81 | MARTIN, L., et al., "Continuous Intravenous Cimetidine Decreases Stress-Related Upper Gastrointestinal Hemorrhage Without Promoting Pneumonia", <u>Critical Care Medicine</u> , Vol. 21, Vol. 1, pp. 19-30 (1993). |
| | C82 | MAXWELL, et al., "Control of Gastric pH In A Critical Care Unit: Physician Behavior and Pharmacologic Effectiveness", <u>Am. Rev. Respir. Dis.</u> , Vol. 143, No. 4 (Part 2), pg. A482 (1991). |
| | C83 | MCANDREWS, et al., "Omeprazole and Lansoprazole Suspensions for Nasogastric Administration", <u>American Journal of Health-System Pharm.</u> , Vol. 56, pg. 81 (January 1, 1999). |
| /CC/ | C84 | MCTAVISH, D., et al., "Omeprazole, An Updated Review of its Pharmacology and Therapeutic Use in Acid-Related Disorders" by <u>Drugs</u> , Vol. 42, No. 1, pp. 138-170 (1991). |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 601.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | |
|---|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| Sheet | 14 | 20 | Attorney Docket Number | 03207556 |

| NON PATENT LITERATURE | | |
|-------------------------|----------|---|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C85 | MEINERS, et al., "Evaluation of Various Techniques to Monitor Intragastric pH", <u>Arch. Surg.</u> , Vol. 117, No. 3, pp. 288-91 (1982). |
| | C86 | METZLER, M., Advances in the use of PPI's From Efficacy to Effectiveness, <u>Presentation: Simplified Omeprazole Suspension</u> (1999). |
| | C87 | MOHIUDDIN, M. A., et al., "Effective Gastric Acid Suppression After Oral Administration of Enteric-Coated Omeprazole Granules", <u>Digestive Diseases and Sciences</u> , Vol. 42, No. 4, pp. 715-719 (April 1997). |
| | C88 | NAKAGAWA, et al., "Lansoprazole - Phase I Study of Lansoprazole (AG-1749) - Antiulcer Agent", <u>Journal of Clinical Therapeutics & Medicines</u> , Vol. 7, No. 1, pp. 33-50 (1991). |
| | C89 | NAKAMURA, M, et al., "Effect of Combined Administration of Lansoprazole and Sofalcone on Microvascular and Connective Tissue Regeneration After Ethanol-induced Mucosal Damage", <u>Journal of Clinical Gastroenterology</u> , Vol. 27, Supp. 1, pp. 170-77 (1998). |
| | C90 | NAUNTON, M., et al., "Overuse of Proton Pump Inhibitors", <u>Journal of Clinical Pharmacy and Therapeutics</u> , Vol. 25, pp. 333-340 (2000). |
| | C91 | OH & CARROLL, "Electrolyte and Acid-base Disorders", <u>The Pharmacologic Approach to the Critically Ill Patient</u> , pp. 957-68 (Chernow, B. ed. 1994). |
| | C92 | OOSTERHUIS, et al. "Omeprazole: Pharmacology, Pharmacokinetics and Interactions", <u>Digestion</u> , Vol. 44, Suppl. 1, pp. 9-17 (1989). |
| | C93 | OSLER, et al., "Effect of Omeprazole On The Phosphate-Binding Capacity of Calcium Carbonate", <u>Nephron</u> , Vol. 69, pp. 89-90 (1995). |
| | C94 | OSTRO, et al., "Control of Gastric pH With Cimetidine: Boluses Versus Primed Infusions", <u>Gastroenterology</u> , Vol. 89, No. 3, pp. 532-37 (1985). |
| | C95 | PAUL, J., et al., "Pantoprazole Bicarbonate Suspension (PBS) Provides Oral Bioavailability Comparable To Tablet", <u>Critical Care Medicine</u> , (Feb. 2001). |
| | C96 | PECKMAN, H., "Alternative method for administering proton-pump inhibitors through nasogastric tubes" <u>Am J Health-Syst Pharm</u> Vol. 56, pp. 1020, (May 15 1999). |
| | C97 | PEURA & JOHNSON, "Cimetidine for Prevention and Treatment of Gastroduodenal Mucosal Lesions in Patients In an Intensive Care Unit", <u>Ann. Intern. Med.</u> , Vol. 103, pp. 173-177 (1985). |
| | C98 | PHILLIPS, D. H., "Interaction of Omeprazole with DNA in Rat Tissues", <u>Mutagenesis</u> , Vol. 7, No. 4, pp. 277-283 (July 1992). |
| | C99 | PHILLIPS, J., & METZLER, M., Poster Presentation presented at the Society for Critical Care Medicine Annual Meeting relating to SOS, (Jan 1999). |
| /CC/ | C100 | PHILLIPS, J., et al., "A Multicenter, Prospective, Randomized Clinical Trial of Continuous Infusion I.V. Ranitidine vs. Omeprazole Suspension In the Prophylaxis of Stress Ulcers", <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), p. A101, No. 222 (1998). |
| 1334284.1 /Celia Chang/ | | Date Considered 06/14/07 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-766-9199) and select option 2.

| | | | | |
|---|----|----|--------------------------|-------------------|
| Substitute for form 1448/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| Sheet | 15 | 20 | Attorney Docket Number | 03207556 |

| NON PATENT LITERATURE | | |
|-----------------------|---------------|---|
| Examiner Initials* | Cite No. | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C101 | PHILLIPS, J., et al., "A Prospective Study of Simplified Omeprazole Suspension for the Prophylaxis of Stress-related Mucosal Damage", <u>Critical Care Medicine</u> , Vol. 24, No. 11, pp. 1793-1800 (1996). |
| | C102 | PHILLIPS, J., et al., "Simplified Omeprazole Solution For The Prophylaxis of Stress-Related Mucosal Damage In Critically Ill Patients", <u>Critical Care Medicine</u> , Vol. 22, No. 1, p. A53 (January 1994). |
| | C103 | PHILLIPS, J., et al., "The Stability of Simplified Lansoprazole Suspension (SLS)", <u>Gastroenterology</u> , Vol. 116, No. 4, pg. G0382 (April 1999). |
| | C104 | PHILLIPS, J., et al., "The Stability of Simplified Omeprazole Suspension (SOS)", <u>Critical Care Medicine</u> , Vol. 26, No. 1 (Suppl.), pg. A101, No. 221 (1998). |
| | C105 | PHILLIPS, J., Presentation: " Problems with Administering Granules", <u>Overview of Omeprazole Suspension</u> , (1999/2000). |
| | C106 | PHILLIPS, J., Presentation: "From Efficacy to Effectiveness Alternative Dosing of PPI's, <u>Overview of Omeprazole Suspension</u> , (Aug 1998). |
| | C107 | PHILLIPS, J., Presentation: "Simplified Omeprazole Suspension (SOS)", (1998). |
| | C108 | PHILLIPS, J., Presentation: "Stress-related Mucosal Damage, Optimizing Drug Therapy, <u>Prophylaxis of Stress Ulcers</u> , (1997) |
| | C109 | PHILLIPS, J., Presentation: "Stress-related Mucosal Damage, Optimizing Drug therapy in the 1990's, <u>The University of Missouri Surgical Society Scientific Program</u> , (June 1994). |
| | C110 | PHILLIPS, J., Presentation: "Update on Acid-related Disorders, Optimizing Pharmacotherapy for the 1990's, <u>A Model for Optimizing Pharmacotherapy</u> , (1996) |
| | C111 | PHILLIPS, Project #5122: "Simplified Omeprazole Solution (S.O.S.) - Pharmacokinetic/Pharmacodynamic Study in Patients at Risk for Stress Related Mucosal Damage (SRMD)" (Approved 4/28/94). |
| | C112 | PHILLIPS, J. et al., " <u>Flavored lansoprazole Suspension in Pediatric Gerd.</u> ", <u>Journal of Pediatric Gastroenterology and Nutrition</u> , Vol. 31, Supp. 2 (December 2000) |
| | C113 | PHILLIPS, J. et al., Abstract of " <u>A Randomized, Cross-over Study of Duodenal or Jejunal Compared to Nasogastric Administration of Omeprazole Suspension in Critically Ill Patients</u> ", <u>Pharmacotherapy, The Journal of Human Pharmacology and Drug Therapy</u> , pp. 1237 (October 6, 2000) |
| | C114 | PHILLIPS, J. et al., " <u>Use of Flavored Lansoprazole or Omeprazole Suspensions in Pediatric Gerd.</u> ", Supplement to <u>Gastroenterology</u> , Vol. 18 (April 2000) |
| | C115 | PHILLIPS, J. et al., Abstract for " <u>A Randomized, Crossover Study of Duodenal or Jejunal Compared to Nasogastric Administration of Omeprazole Suspension in Critically Ill Patients</u> ", <u>The Journal of Human Pharmacology and Drug Therapy</u> , Vol. 20, Number 10, p. 1237 (October 2000) |
| /CC/ | C116 | PHILLIPS, J. et al., " <u>Use of Flavored Lansoprazole or Omeprazole Suspensions in Pediatric Gerd</u> ", Supplement to <u>Gastroenterology</u> , (May 2000) |
| 1334284.1 | /Celia Chang/ | Date Considered 06/14/07 |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-6199 (1-800-786-6199) and select option 2.

| | | | |
|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/722,184 |
| | | Filing Date | November 25, 2003 |
| | | First Named Inventor | Phillips |
| | | Art Unit | 1625 |
| | | Examiner Name | Celia C. Chang |
| | | Attorney Docket Number | 03207556 |
| Sheet | 16 | 20 | |

| NON PATENT LITERATURE | | |
|-----------------------|-----------|--|
| Examiner Initials* | Cite No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| ICC/ | C117 | PICKWORTH, et al., "Occurrence of Nosocomial Pneumonia in Mechanically Ventilated Trauma Patients: A Comparison of Sucralfate and Ranitidine", <u>Critical Care Medicine</u> , Vol. 21, No.12, , pp. 1856-62 (1993). |
| | C118 | PILBRANT, "Principles for Development of Antacids", <u>Scand. J. Gastroenterol Suppl.</u> , Vol. 75, pp. 32-36 (1982). |
| | C119 | PILBRANT, A., et al., "Development of An Oral Formulation of Omeprazole", <u>Scand. J. Gastroenterol</u> , Vol. 20, (Suppl. 108) pp. 113-120 (1985). |
| | C120 | PIPKIN, et al., "Onset of Action of Antisecretory Drugs: Beneficial Effects of a Rapid Increase in Intragastric pH in Acid Reflux Disease", <u>Scand. J. Gastroenterol. Supp.</u> , Vol. 230, pp. 3-8 (1999). |
| | C121 | Presentation on Overview of Omeprazole Suspension, "Pharmacotherapy Related Outcomes Group Researching Effective Stress ulcer Strategies, (2000). |
| | C122 | Presentation on Overview of Omeprazole Suspension, Stress Ulcer Prophylaxis in the 21 st Century", (2001). |
| | C123 | PRICHARD, et al., "Omeprazole: A Study of Its Inhibition of Gastric pH and Oral Pharmacokinetics After Morning or Evening Dosage", <u>Gastroenterology</u> , Vol. 88, Part 1, pp. 64-69 (1985). |
| | C124 | PRIEBE & SKILLMAN, "Methods of Prophylaxis in Stress Ulcer Disease", <u>World J. Surg.</u> , Vol. 5, Part 2, pp. 223-33 (March 1981). |
| | C125 | QUERCIA, R. A., et al., "Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid", <u>American Journal of Health-System Pharmacy</u> , Vol. 54, pp. 1833-1836 (August 15, 1997). |
| | C126 | REGARDH, C., et al., "The Pharmacokinetics of Omeprazole in Humans - A Study of Single Intravenous and Oral Doses", <u>Therapeutic Drug Monitoring</u> , Vol. 12, No. 2, pp. 163-172 (1990). |
| | C127 | REGARDH, et al., "Pharmacokinetics and Metabolism of Omeprazole in Animals and Man - An Overview", <u>Scand. J. Gastroenterology</u> , Vol. 108, pp. 79-94 (1985). |
| | C128 | RODRIGO, et al., "Therapeutic Approach to Peptic Ulcer Relapse", <u>Methods Find Exp. Clinical Pharmacology</u> , Vol. 11 (Supp. 1), pp. 131-135 (1989). |
| ICC/ | C129 | ROHAN, E., "Nasogastric Administration of Omeprazole", <u>The Australian Journal of Hospital Pharmacy</u> , Vol. 28, No. 3, pp. 174-176 (1998). |
| | C130 | ROY, P., et al., "Zollinger-Ellison Syndrome - Clinical Presentation in 261 Patients", <u>Medicine</u> , Vol. 79, No. 6, pp. 379-411 (2000). |
| | C131 | RYAN, et al., "Nosocomial Pneumonia During Stress Ulcer Prophylaxis With Cimetidine and Sucralfate", <u>Arch. Surg.</u> , Vol. 128, pp. 1353-57 (December 1993). |
| | C132 | SAX, "Clinically Important Adverse Effects and Drug Interactions With H2-receptor Antagonists: An Update", <u>Pharmacotherapy</u> , Vol. 7, No. 6, Part 2, pp. 110S-115S (1987). |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). *See Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbol(s) as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. This information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
If you need assistance in completing this form, call 1-800-PTO-0199 (1-800-785-0199) and select option 2.

| | | | | |
|---|----|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | Application Number | 10/722,184 |
| | | | Filing Date | November 25, 2003 |
| | | | First Named Inventor | Phillips |
| | | | Art Unit | 1625 |
| | | | Examiner Name | Celia C. Chang |
| Sheet | 17 | 20 | Attorney Docket Number | 03207556 |

| NON PATENT LITERATURE | | |
|-----------------------|-----------------------|---|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| ICC/ | C133 | SCHEPP, "Stress Ulcer Prophylaxis: Still a Valid Option in the 1990s?", <u>Digestion</u> , Vol. 54, No. 4, pp. 189-99 (1993). |
| | C134 | SCHMASSMANN, et al., "Antacid Provides Better Restoration of Glandular Structures Within the Gastric Ulcer Scar Than Omeprazole", <u>Gut</u> , Vol. 35, No. 7, pp. 896-904 (July 1994). |
| | C135 | SCHMASSMANN, et al., "Antacids in Experimental Gastric Ulcer Healing: Pharmacokinetics of Aluminum and Quality of Healing", <u>European Journal of Gastroenterology & Hepatology</u> , Vol. 5, Suppl. 3, pp. S111-S116 (1993). |
| | C136 | SCHUMAN, et al., "Prophylactic Therapy for Acute Ulcer Bleeding: A Reappraisal", <u>Annals of Internal Medicine</u> , Vol. 106, Vol. 4, pp. 562-67 (1987). |
| | C137 | SCHUSTER, "Stress Ulcer Prophylaxis: In Whom? With What?", <u>Critical Care Medicine</u> , Vol. 21, Part 1, pp. 4-6 (January 1993). |
| | C138 | SECHET, et al., "Inhibition of Gastric Secretion by Omeprazole and Efficacy of Calcium Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis", <u>Nephrologie</u> , Vol. 20, No. 4, pp. 213-216 (1999). |
| | C139 | SECHET, et al., Role of the Time of Administration of Calcium Carbonate in the Control of Hyperphosphatemia in Patients on Maintenance Hemodialysis", <u>Nephrologie</u> , Vol. 20, No. 4, pp. 209-212 (1999). |
| | C140 | SHARMA, et al., "Oral Pharmacokinetics of Omeprazole and Lansoprazole After Single and Repeated Doses as Intact Capsules or As Suspensions in Sodium Bicarbonate", <u>Alimentary Pharmacology & Therapeutics</u> , Vol. 14, No. 7, pp. 887-892 (July 2000). |
| | C141 | SHARMA, et al., "The Pharmacodynamics of Lansoprazole Administered Via Gastrostomy as Intact, Non-Encapsulated Granules", <u>Alimentary Pharmacology Therapy</u> , Vol. 12, pp. 1171-1174 (1998). |
| | C142 | SHARMA, V., et al., "Effect on 24-hour Intragastric Acidity of Simplified Omeprazole Solution (SOS) Administered Via Gastrostomy", <u>AJG</u> , Vol. 92, No. 9, p. 1625, Section 169 (1997). |
| | C143 | SHARMA, V., et al., "Simplified Lansoprazole Suspension - A Liquid Formulation of Lansoprazole - Effectively Suppresses Intragastric Acidity When Administered Through a Gastrostomy", <u>The American Journal of Gastroenterology</u> , Vol. 94, No. 7, pp. 1813-1817 (July 1999). |
| | C144 | SHARMA, V., et al., "Simplified Lansoprazole Suspension (SLS): A Proton Pump Inhibitor (PPI) In A Liquid Formulation That Works", <u>AJG</u> , p. 1647, Section 153 (September 1998). |
| ICC/ | C145 | SHARMA, V., et al., "The Effects on Intragastric Acidity of Per-Gastrostomy Administration of An Alkaline Suspension of Omeprazole", <u>Aliment Pharmacol Ther.</u> , Vol. 13, pp. 1091-1095 (1999). |

| | | |
|-----------|---------------|--------------------------|
| 1334284.1 | /Celia Chang/ | Date Considered 06/14/07 |
|-----------|---------------|--------------------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-0199 (1-800-786-9199) and select option 2.

| | | | |
|---|----|--------------------------|-------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 10/722,184 |
| | | Filing Date | November 25, 2003 |
| | | First Named Inventor | Phillips |
| | | Art Unit | 1625 |
| | | Examiner Name | Celia C. Chang |
| | | Attorney Docket Number | 03207556 |
| Sheet | 18 | 20 | |

| NON PATENT LITERATURE | | |
|-----------------------|-----------------------|---|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| ICC/ | C146 | SHARMA, V., "Comparison of 24-hour Intra-gastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole", <u>American Journal of Health-System Pharmacists</u> , Vol. 56, Suppl 4, pp. S18-S21 (December 1, 1999). |
| | C147 | SIEPLER, "A Dosage Alternative for H-2 Receptor Antagonists, Continuous-Infusion", <u>Clinical Therapy</u> , Vol. 8, Suppl. A, pp. 24-33 (1986). |
| | C148 | SIEPLER, et al., "Selecting Drug Therapy for Patients With Duodenal Ulcers", <u>Clinical Pharmacy</u> , Vol. 9, No. 6, pp. 463-467 (June 1990). |
| | C149 | SIH, J., et al., "Studies on (H(+)-K+)-ATPase Inhibitors of Gastric Acid Secretion. Prodrugs of 2-[(2-Pyridinylmethyl)sulfinyl]benzimidazole Proton-Pump Inhibitors", <u>Journal of Medicinal Chemistry</u> , Vol. 34, No. 3, pp. 1049-1062 (March 1991). |
| | C150 | SIMMS, et al., "Role of Gastric Colonization in the Development of Pneumonia in Critically Ill Trauma Patients: Results of a Prospective Randomized Trial", <u>The Journal of Trauma</u> , Vol. 31, No. 4, pp. 531-36 (1991). |
| | C151 | SKILLMAN, et al., "Respiratory Failure, Hypotension, Sepsis and Jaundice: A Clinical Syndrome Associated With Lethal...", <u>Am. J. Surg.</u> , Vol. 117, Vol. 4, pp. 523-30 (1969). |
| | C152 | SKILLMAN, et al., "The Gastric Mucosal Barrier: Clinical and Experimental Studies In Critically Ill and Normal Man...", <u>Ann. Surg.</u> , Vol. 172, Vol. 4, pp. 564-84 (1970). |
| | C153 | SMYTHE & ZAROWITZ, "Changing Perspectives of Stress Gastritis Prophylaxis", <u>The Annals of Pharmacotherapy</u> , Vol. 28, pp. 1073-84 (September 1994). |
| | C154 | SPENCER, C., et al., "Esomeprazole", <u>Drugs 2000</u> , Vol. 60, No. 2, pp. 321-329 (August 2000). |
| | C155 | SPYCHAL & WICKMAN, "Thrombocytopenia Associated With Rantidine", <u>British Medical Journal</u> , Vol. 291, p. 1687 (December 14, 1985). |
| | C156 | STRATFORD, M. R., et al., "Nicotinamide Pharmacokinetics in Humans: Effect of Gastric Acid Inhibition, Comparison of Rectal vs Oral Administration and the Use of Saliva for Drug Monitoring", <u>Br. J. Cancer</u> , Vol. 74, No. 1, pp. 16-21 (July 1996). |
| | C157 | TAKEUCHI, et al., "Effects of Pantoprazole, A Novel H+/K+-ATPase Inhibitor, On Duodenal Ulcerogenic and Healing Responses in Rats: A Comparative Study with Omeprazole and Lansoprazole", <u>Journal of Gastroenterology and Hepatology</u> , Vol. 14, No. 3, p. 251-57 (1999). |
| | C158 | TANAKA, et al., "Pathogenesis of The Earliest Epithelial Cell Damage Induced by Mepirlzole and Cysteamine in the Rat Duodenum", <u>Japanese Journal of Pharmacology</u> , Vol. 51, No. 4, pp. 509-519 (December 1989). |
| ICC/ | C159 | TANAKA, M., et al., "Differential Stereoselective Pharmacokinetics of Pantoprazole, a Proton Pump Inhibitor in Extensive and Poor Metabolizers of Pantoprazole - A Preliminary Study", <u>Chirality</u> , Vol. 9, pp. 17-21 (1997). |

| | | | |
|-----------|---------------|-----------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|-----------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Ind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-0199 (1-800-786-0196) and select option 2.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

| | |
|------------------------|-------------------|
| Application Number | 10/722,184 |
| Filing Date | November 25, 2003 |
| First Named Inventor | Phillips |
| Art Unit | 1625 |
| Examiner Name | Celia C. Chang |
| Attorney Docket Number | 03207556 |

Sheet 19 20

NON PATENT LITERATURE

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
|--------------------|-----------------------|--|
| ICC/ | C160 | THOMSON, "Are The Orally Administered Proton Pump Inhibitors Equivalent? A Comparison of Lansoprazole, Omeprazole, Pantoprazole, and Rabeprazole", <u>Current Gastroenterology Reports</u> , Vol. 2, No. 6, pp. 482-493 (December 2000). |
| | C161 | Trilateral Project B3b, "Reach Trough Claims", pp. 1-28 (2001) |
| | C162 | TRYBA, "Risk of Acute Stress Bleeding and Nosocomial Pneumonia in Ventilated Intensive Care Patients. Sucralfate vs. Antacids", <u>American Journal of Medicine</u> , Vol. 87 (3B) 117-24 (1987). |
| | C163 | TRYBA, "Stress Ulcer Prophylaxis - Quo Vadis?", <u>Intensive Care Medicine</u> , Vol. 20, pp. 311-13 (1994). |
| | C164 | TYTGAT, G., "Drug Therapy of Reflux Oesophagitis: An Update," <u>Scand J. Gastroenterol.</u> , Vol. 24 (Suppl.168), pp. 38-49 (1989). |
| | C165 | VIAL, et al., "Side Effects of Ranitidine", <u>Drug Safety</u> , Vol. 6, pp. 94-117 (March/April 1991). |
| | C166 | VINCENT, et al., "Concurrent Administration of Omeprazole and Antacid Does Not Alter The Pharmacokinetics and Pharmacodynamics Of Dofetilide In Healthy Subjects", <u>Clinical Pharmacology & Therapeutics</u> , Vol. 59, No. 2 (P11-93), pg. 182 (February 1996). |
| | C167 | WADE, Organic Chemistry, Pritice-Hall, Inc., Chapter 8, p. 349 (1987). |
| | C168 | WALAN, "Pharmacological Agents For Peptic Ulcer Disease", <u>Scand. J. Gastroenterol. Suppl.</u> , Vol. 19, No. 98, pg. 1 (1984). |
| | C169 | WALLMARK, et al., "The Relationship Between Gastric Acid Secretion and Gastric H ⁺ /K ⁺ -ATPase Activity", <u>Journal of Biological Chemistry</u> , Vol. 260, No. 25, pp. 13681-84 (1985). |
| | C170 | WATANABE, K., et al., "Pharmacokinetic Evaluation of Omeprazole Suspension Following Oral Administration in Rats: Effect of Neutralization of Gastric Acid", <u>Acta Med Okayama</u> , Vol. 50, No. 4, pp. 219-222 (August 1996). |
| | C171 | WHIPPLE, J., et al., "The Effect of Omeprazole/Sodium Bicarbonate Solution Administration on the Accuracy of Subsequent pH Measurements Through the Nasogastric Tube", <u>Critical Care Medicine</u> , Vol. 23, No. 1 Supplement, p. A69 (January 1995). [Date stamped in University of Missouri Health Sciences Library January 6, 1995]. |
| | C172 | WILDER-SMITH & MERKI, "Tolerance During Dosing with H ₂ Receptor Antagonists: An Overview", <u>Scand. J. Gastroenterol.</u> , Vol. 193, pp. 14-19 (1992). |
| ICC/ | C173 | YAMAKAWA, T., "Synthesis and Structure-Activity Relationships of Substituted 2-[2-imidazolylsulfanyl)methyl] Anilines As A New Class of Gastric H ⁺ /K ⁺ -ATPase Inhibitors. II.", <u>Chem Pharm Bull</u> (Tokyo), Vol. 40, No. 3, pp. 675-682 (March 1992). |

1334284.1

/Celia Chang/

Date
Considered

06/14/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Ind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

| | | | | | |
|---|----|--------------------------|-------------------|------------------------|----------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Complete if Known | | | |
| | | Application Number | 10/722,184 | | |
| | | Filing Date | November 25, 2003 | | |
| | | First Named Inventor | Phillips | | |
| | | Art Unit | 1625 | | |
| | | Examiner Name | Celia C. Chang | | |
| Sheet | 20 | | 20 | Attorney Docket Number | 03207556 |

| NON PATENT LITERATURE | | |
|-----------------------|--------------|--|
| Examiner Initials* | Cite No.† | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |
| /CC/ | C174 | YASUDA, et al., "Antacids Have No Influence on the Pharmacokinetics of Rabeprazole, A New Proton Pump Inhibitor, In Healthy Volunteers", <u>International Journal of Clinical Pharmacology and Therapeutics</u> , Vol. 37, No. 5, pp. 249-253 (1999). |
| /CC/ | C175 | ZINNER, et al., "The Prevention of Upper Gastro-Intestinal Tract Bleeding in Patients in an Intensive Care Unit", <u>Surgery, Gynecology and Obstetrics</u> , Vol. 153, pp. 214-20 (August 1981). |

| | | | |
|-----------|---------------|--------------------|----------|
| 1334284.1 | /Celia Chang/ | Date Considered | 06/14/07 |
|-----------|---------------|--------------------|----------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ***Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-0199 (1-800-780-9199) and select option 2.

| | | | |
|--|------|--------------------------|-------------------|
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Complete if Known | |
| | | Application Number | 10/722,184 |
| | | Filing Date | November 25, 2003 |
| | | First Named Inventor | Phillips, J. |
| | | Art Unit | 1625 |
| | | Examiner Name | Chang, Celia |
| Sheet 1 | of 1 | Attorney Docket Number | 03207556 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| /CC/ | | Oct. 2, 2007, First Amended Complaint For Patent Infringement, Santarus, Inc. and The Curators of the University of Missouri v. Par Pharmaceutical, Inc. with Exhibits A - D. | |
| | | Sep. 18, 2007, Ex Parte Reexamination Certificate for U.S. Patent No. 6, 699,885. | |
| | | Sep. 14, 2007, Report on the Filing or Determination of an Action Regarding a Patent or Trademark. | |
| | | Sep. 13, 2007, Complaint For Patent Infringement, Santarus, Inc. and The Curators of the University of Missouri v. Par Pharmaceutical, Inc. with Exhibits A - C. | |
| | | Aug. 3, 2007, Letter from Par Pharmaceutical to Santarus Inc. and The Curators of the University of Missouri. | |
| | | Mar. 12, 2007, Notice of Intent to Issue Ex Parte Reexamination Certificate for U.S. Patent No. 6,699,885 and Statement of Reasons for Patentability and/or Confirmation. | |
| | | Aug. 22, 2005 - Mar. 12, 2007, File History of U.S. Patent Application No. 90/007,686: Ex Parte Reexamination of U.S. Patent No. 6,699,885. | |
| /CC/ | | Oct. 17, 2007, Answer and Counterclaims filed by Par Pharmaceutical. | |
| | | | |
| | | | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Celia Chang/ | Date Considered | 01/22/2008 |
|--------------------|---------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.